Current Headlines

1. Alloy Therapeutics Enters Into Agreement To Advance Novel Antibody Discovery Platform 3/17/2026

   Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies.

2. ADDF Launches New Phase Of $150M Diagnostics Accelerator Initiative To Power Next Generation Of Alzheimer's Precision Medicine Worldwide 3/17/2026

   The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional $50 million in funding, bringing the initiative's total to $150 million.

3. Scientists Find Promising Drug Target For Tuberculosis 3/17/2026

   Researchers from Imperial and the London School of Hygiene & Tropical Medicine (LSHTM) have discovered a drug target that could potentially help tackle drug-resistant tuberculosis, one of the biggest causes of death worldwide.

4. Dalriada Drug Discovery And Topos Bio Announce Collaboration To Advance Drug Discovery For Intrinsically Disordered Proteins 3/17/2026

   Dalriada Drug Discovery ("Dalriada"), a partnered discovery organization supporting small-molecule programs from hit identification through lead optimization, and Topos Bio ("Topos"), an AI-native biotechnology company developing therapeutics for intrinsically disordered proteins (IDPs), today announced a research collaboration to accelerate experimental validation for IDP drug discovery using advanced protein mass spectrometry and proteomics.

5. Viva Biotech Accelerates AI-Driven Drug Discovery And Advance The 'Lab-In-The-Loop' With NVIDIA 3/16/2026

   Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of novel therapeutics with AI-driven designs with NVIDIA technology.

6. Cogent Biosciences Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With NonAdvanced Systemic Mastocytosis (NonAdvSM) 3/16/2026

   Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026.

7. Pattern Discovers New microRNA Drug For Treatment Of Glioblastoma Cancer 3/16/2026

   Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, today announced that the Company has discovered a new microRNA (miRNA) drug which has the potential to inhibit several tumor-promoting genes in Glioblastoma (“glioblastoma multiforme” or “GBM”).

8. Biophytis-LynxKite Alliance Expands To Turbocharge AI-Driven Drug Discovery For Next Generation Longevity Therapeutics 3/13/2026

   Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy) and plans to expand the platform to other modalities.

9. PRISM BioLab And Receptor.AI Announce Drug Discovery Collaboration Agreement 3/12/2026

   PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") to develop an integrated, AI-navigated, physics-guided platform for the discovery of orally available small molecules targeting intracellular protein–protein interactions (PPIs), membrane proteins, and complex receptor systems.

10. Queen Mary: Improving The Drug Development Pipeline 3/12/2026

    It takes a long time, many different steps, and considerable cost, before a new drug can be approved for use as a medicine.